Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while KraneShares Electric Vehicles and Future Mobility trades at $30.54. The key difference: KraneShares Electric Vehicles and Future Mobility is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | KARS | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $38.01 |
52-Week Low | $278.09 | $22.89 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
KARS trades at $30.575, up 0.21% today, but technical indicators are bearish with moving averages and oscillators signaling sell pressure. Support levels are clustered around $30, with resistance at $31. Recent news highlights global EV sales growth, particularly in Europe and China, though U.S. adoption lags. Financial ratios are unavailable, limiting fundamental clarity.
The outlook is cautious due to bearish technicals and competitive risks from Chinese EV makers. Upside depends on broader EV adoption and regulatory developments, but tariffs and market volatility pose headwinds. Investors should await earnings data for fundamental validation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
